Centro de Investigación Biomédica de La Rioja-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. The dietary antioxidant piceatannol inhibits adipogenesis of human adipose mesenchymal stem cells and limits glucose transport and lipogenic activities in adipocytes

    International Journal of Molecular Sciences, Vol. 19, Núm. 7

2016

  1. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 567-582

  2. Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 555-566